Comparing Digital Therapeutic Intervention with an Intensive Obesity Management Program: Randomized Controlled Trial



Year of publication 2022
Type Article in Periodical
Magazine / Source Nutrients
Keywords obesity; diabetes mellitus type 2; prevention; digital therapeutics; mobile application; randomized controlled trial; lifestyle intervention; metabolic syndrome; insulin resistance
Description In this study, we evaluated whether the digital program Vitadio achieves comparable results to those of an intensive in-person lifestyle intervention in obesity management. This is a 12-month prospective, randomized controlled trial. Obese patients with insulin resistance, prediabetes or type 2 diabetes were included. The intervention group (IG) used Vitadio. The control group (CG) received a series of in-person consultations. Body weight and various metabolic parameters were observed and analyzed with ANOVA. The trial is ongoing and the presented findings are preliminary. Among 100 participants (29% men; mean age, 43 years; mean BMI, 40.1 kg/m2), 78 completed 3-month follow-up, and 51 have completed the 6-month follow-up so far. Participants significantly (p < 0.01) reduced body weight at 3 months (IG: -5.9 ± 5.0%; CG: -4.2 ± 5.0%) and 6 months (IG: -6.6±6.1%; CG: -7.1 ± 7.1%), and the difference between groups was not significant. The IG achieved favorable change in body composition; significant improvement in TAG (-0.6 ± 0.9 mmol/l, p < 0.01), HDL (0.1 ± 0.1%, p < 0.05), HbA1c (-0.2 ± 0.5%, p < 0.05) and FG (-0.5 ± 1.5 mmol/l, p < 0.05); and a superior (p = 0.02) HOMA-IR reduction (-2.5 ± 5.2, p < 0.01). The digital intervention achieved comparable results to those of the intensive obesity management program. The results suggest that Vitadio is an effective tool for supporting patients in obesity management and diabetes prevention.

You are running an old browser version. We recommend updating your browser to its latest version.

More info